Abstract 927: Gut microbiome changes are associated with the efficacy of Delta-24-RGDOX viroimmunotherapy against malignant glioma

Volume: 81, Pages: 927 - 927
Published: Jul 1, 2021
Abstract
Malignant gliomas are devastating diseases that require new and more effective treatments. To improve clinical outcomes, our laboratories have developed an oncolytic adenovirus armed with the T-cell activator OX40L, named Delta-24-RGDOX. Here, we evaluated changes to gut microbiome in glioma bearing mice treated with viroimmunotherapy. GL261 glioblastoma cells were implanted in the brain of immunocompetent C57BL/6 mice. Then mice were treated...
Paper Details
Title
Abstract 927: Gut microbiome changes are associated with the efficacy of Delta-24-RGDOX viroimmunotherapy against malignant glioma
Published Date
Jul 1, 2021
Volume
81
Pages
927 - 927
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.